No Data
Xianju Pharmaceutical: Report for the third quarter of 2024
Zhejiang Xianju Pharmaceutical (002332.SZ): The net income for the first three quarters was 0.53 billion yuan, a year-on-year increase of 12.42%.
格隆汇October 25th, zhejiang xianju pharmaceutical (002332.SZ) announced its third quarter report for 2024, with the company achieving revenue of 3.237 billion yuan in the first three quarters, a decrease of 0.01% year-on-year; net income attributable to the shareholders of the listed company was 0.53 billion yuan, an increase of 12.42% year-on-year; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.521 billion yuan, an increase of 12.82% year-on-year; basic earnings per share were 0.5360 yuan.
GF Securities: The price of active pharmaceutical ingredients stabilizes at the bottom, with a slight increase in double bond prices.
In 2024, with relatively low inventory levels, some downstream formulation companies began to replenish their stockpiles. In addition, the continuous release of new active pharmaceutical ingredients after the expiration of patents, the sector is in a bottoming out stable recovery state.
Zhejiang Xianju Pharmaceutical (002332.SZ): The drug registration application for Levosimendan Hydrochloride Tablets has been accepted.
格隆汇 October 16th 丨 Zhejiang Xianju Pharmaceutical (002332.SZ) announced that the company recently received a notice of acceptance of the registration of domestically produced pharmaceutical products containing the active ingredient Betahistine Mesilate Tablets issued by the National Medical Products Administration. Betahistine Mesilate Tablets, with a specification of 6mg, is a reference preparation for the original innovative drug, with Weikang (China) Pharmaceutical Co., Ltd. as the marketing authorization holder, known as Betahistine Mesilate Tablets/敏使朗 in English/commodity name. Betahistine Mesilate Tablets was initially developed by Japan Eisai Co., Ltd., marketed under the brand name Merislon.
A Piece Of The Puzzle Missing From Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Share Price
Zhejiang Xianju Pharmaceutical (002332.SZ): The consistency evaluation of Newcetam Sodium Injection was approved.
As of October 14, Gelonhui reported that Zhejiang Xianju Pharmaceutical (002332.SZ) recently received the "Drug Supplementary Application Approval Letter" (Notification Number: 2024B047132024B04714) issued by the National Medical Products Administration regarding the supplementary application for the approval of Aceglutamide Sodium for Injection. The Aceglutamide Sodium for Injection of the company has passed the generic drug quality and efficacy consistency evaluation.
Little Excitement Around Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Earnings As Shares Take 27% PoundingNo Data
No Data
